NTEC Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel...

Stats
Šios dienos apimtis	988 303
Vidutinė apimtis	1.05M
Rinkos kapitalizacija	0.00
EPS	$0 ( 2021-08-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.345 (3.58%)

Insider Trading

Date	Person	Action	Amount	type
2021-07-23	Hayes William B	Sell	250	Stock Option (right to buy)
2021-07-23	Hayes William B	Sell	250	Stock Option (right to buy)
2021-07-23	Hayes William B	Sell	500	Stock Option (right to buy)
2021-07-23	Karah Hila	Sell	281	Stock Option (right to buy)
2021-07-23	Karah Hila	Sell	250	Stock Option (right to buy)

INSIDER POWER
0.00
Last 59 transactions
Buy: 3 599 185 \| Sell: 7 817 315

Tūris Koreliacija

Ilgas: 0.44 (neutral)

Trumpas: 0.85 (strong)

Signal:(64.456) Same movement expected

Intec Pharma Ltd Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Intec Pharma Ltd Koreliacija - Valiuta/Žaliavos

0.42
( neutral )

0.46
( neutral )

-0.20
( neutral )

0.28
( neutral )

-0.36
( neutral )

-0.32
( neutral )

Intec Pharma Ltd Finansinės ataskaitos

Annual	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-14.30

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-14.30

FY	2019
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-112.74

FY	2018
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-111.67

Financial Reports:

No articles found.

Intec Pharma Ltd

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.